Medibuilder

About Medibuilder

Medibuilder is a medical accelerator and Management Service Organization (MSO) founded in March 2022 by co-CEOs Seung-hyun Kim and Jun-young In. The company specializes in providing comprehensive support for the non-clinical operations of partner hospitals to facilitate rapid growth. Its business model, referred to as the 'Partners Model,' involves establishing joint ventures with hospitals to align interests and form long-term partnerships. Through these partnerships, Medibuilder manages and enhances various non-treatment aspects of hospital operations, including operational efficiency, marketing strategies, and brand development.

The company's approach separates the clinical and business management aspects of a hospital, allowing medical professionals to focus on patient care while Medibuilder handles the acceleration of the business. This model has reportedly led to significant increases in monthly revenue for its partner hospitals. Medibuilder also focuses on expanding into new business areas by leveraging the medical brands of its partner clinics, with ventures in e-commerce, IT, and finance. A key area of future growth is targeting the K-medical market by launching new hospital brands for foreign medical tourists, enhancing global marketing, and developing AI-powered chatbots for multilingual consultations.

Financially, Medibuilder has demonstrated significant traction in a conservative investment market. After its establishment in 2022, it secured 13 billion KRW through pre-Series A and Series A funding rounds in 2023. In June 2025, the company raised an additional 14 billion KRW in a Series B round, bringing its total accumulated funding to 27 billion KRW. This Series B funding included participation from the Korea Development Bank, a first for a company in the MSO industry, as well as follow-on investment from LB Investment.